Sunday, March 05, 2023 4:50:00 PM
Poor Man, I would expect to see a series of amended complaint(s) as discovery proceeds.
I would not be surprised to see a negligence cause of action for failure to properly supervise employees.
Firms also have a duty to detect customers' manipulative behavior wherein groups of its customers have acted in concert to manipulate a stock. Firms simply can't say "we have no responsibility here because we were simply filling customer orders." Both of these actions are subject to FINRA rules. And failure to detect red flags of customer behavior has been applied in situations where groups of customers have repeatedly acted in concert to manipulate the price of a security, very often a microcap security. So, I would expect a negligence cause of action for one or both as discovery proceeds. Should be interesting.
Unfortunately, I believe the resolution of this litigation is years away.
Three Amigos??? How about "The Sting".
Regards.
I would not be surprised to see a negligence cause of action for failure to properly supervise employees.
Firms also have a duty to detect customers' manipulative behavior wherein groups of its customers have acted in concert to manipulate a stock. Firms simply can't say "we have no responsibility here because we were simply filling customer orders." Both of these actions are subject to FINRA rules. And failure to detect red flags of customer behavior has been applied in situations where groups of customers have repeatedly acted in concert to manipulate the price of a security, very often a microcap security. So, I would expect a negligence cause of action for one or both as discovery proceeds. Should be interesting.
Unfortunately, I believe the resolution of this litigation is years away.
Three Amigos??? How about "The Sting".
Regards.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
